Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High‐Dosage L. reuteri in H. pylori ‐Infected Adults
Helicobacter · 2025
DOI: 10.1111/hel.70064 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2025. Verfasst von Stefano Bibbò und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Limosilactobacillus reuteri, Helicobacter Infections, Proton Pump Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Helicobacter pylori eradication therapy typically consists of a combination of antibiotics and an antisecretory drug. Probiotics may be added to reduce side effects and possibly improve outcomes. Materials and Methods We conducted a double‐blind, randomized trial of pantoprazole plus either Lactobacillus reuteri (Gastrus) (high dose) or a matching placebo to assess the impact on the gut microbiota of H. pylori ‐positive adults. Fecal samples were collected at baseline and after one and 2 months for shotgun metagenomic sequencing.
Results
A total of 26 patients were recruited and completed therapy. L. reuteri was only detected in the group that received supplemental L. reuteri and only at the 1‐month post‐treatment interval. L. reuteri failed to colonize for long‐term the gut, and challenge with L. reuteri failed to alter alpha‐diversity (Shannon index) or beta‐diversity (community ordination) metrics at any time point. Machine learning (PLS‐DA) analysis identified the presence of L. reuteri as the most distinguishing feature at 1 month. No other taxa showed a significant difference between groups.
Conclusion
Short‐term administration of pantoprazole and L. reuteri had no lasting effects on gut microbial composition. While L. reuteri transiently bloomed during supplementation, the overall gut microbiota showed resilience, returning to baseline shortly after therapy. Trial Registration Identifier: NCT03404440
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
- Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Solna, Sweden.
- Baylor College of Medicine, Houston, Texas, USA.
ORCID-Profile: Giovanni Mario Pes, Maria Pina Dore
Zitieren
APA
Bibbò, S., Ahlström, G., Pes, G. M., Graham, D. Y., Engstrand, L., Merola, E., & Dore, M. P. (2025). Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High‐Dosage L. reuteri in H. pylori ‐Infected Adults. Helicobacter. https://doi.org/10.1111/hel.70064
Vancouver
Bibbò S, Ahlström G, Pes GM, Graham DY, Engstrand L, Merola E, et al. Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High‐Dosage L. reuteri in H. pylori ‐Infected Adults. Helicobacter. 2025. doi:10.1111/hel.70064
BibTeX
@article{Bibb2025,
author = {Bibbò, Stefano and Ahlström, Gustav and Pes, Giovanni Mario and Graham, David Y and Engstrand, Lars and Merola, Elettra and Dore, Maria Pina},
title = {Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High‐Dosage L. reuteri in H. pylori ‐Infected Adults},
journal = {Helicobacter},
year = {2025},
doi = {10.1111/hel.70064}
}
EUVIMED